The Lancet reports successful Phase III study of Bexsero vaccine (Novartis)against MenB

The Lancet published findings online from a pivotal Phase III clinical trial of Bexsero (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) from Novartis, involving 3,630 infants from two months of age. The study showed that Bexsero demonstrated a protective immune response and has an acceptable safety profile when administered as a three-dose primary series concomitantly with routine vaccines. The investigators also observed a robust booster response in toddlers to a fourth dose administered at 12 months, which may contribute to an extended duration of protection. These data were first presented in 2010 at the 17th International Pathogenic Neisseria Conference (IPNC). Bexsero is CHMP recommended in the EU.